期刊文献+

丙型肝炎患者HCV—RNA载量与免疫球蛋白及补体表达水平的相关性 被引量:3

Correlations between viral load and the expression level of immunoglobulins and complements in patients with hepatitis C
原文传递
导出
摘要 目的探讨丙型肝炎患者HCV-RNA载量与免疫球蛋白及补体表达水平的相关性。方法收集2014年6月至2016年5月西安市第九医院收治的丙型肝炎患者132例作为研究对象,对其进行HCV—RNA病毒载量检测,按照检测结果将其分为低载量、中载量以及高载量组,对各组进行免疫球蛋白IgA、IgG、IgM检测以及补体C3、C4检测,分析丙肝患者病毒载量与免疫球蛋白及补体水平的相关性。结果丙型肝炎患者IgA、IgG、IgM表达量分别为[(3.95±0.72)g/L,(19.33±4.64)g/L及(2.93±0.50)g/L],高于健康对照组的表达量[(2.13±0.51)g/L,(11.25±2.63)g/L及(1.21±0.35)g/L],C3、C4表达量分别为[(0.82±0.19)g/L及(0.13±0.08)g/L],低于健康对照组[(1.20±0.31)g/L及(0.27±0.11)g/L],差异有统计学意义(P〈0.05)。不同病毒载量患者免疫球蛋白及补体表达水平存在差异(P〈0.05)。Pearson相关性分析结果显示,HCV—RNA病毒载量与血清免疫球蛋白表达水平呈正相关,与血清补体表达水平呈负相关(P〈0.05)。结论不同病毒载量丙型肝炎患者具有不同的免疫球蛋白及补体表达水平,应当尽量控制HCV-RNA病毒载量,从而减少免疫损伤。 Objective To explore the correlations between Hepatitis C viral load (HCV-RNA) and ex- pression level of Immunoglobulin and complements in patients with hepatitis C. Methods 132 patients with hepatitis C accepted in our hospital from Jun. 2014 to May 2016 were divided into low load-group, medium-load group and high-load group according to viral load. The expression level of IgA, IgG, IgM, and complements C3 and G4 of each group were tested to anlayze the correlations between viral load and Ig and complements. Results The levels of IgA, IgG and IgM of patients with hepatitis C were (3.95 ± 0.72) g/L, ( 19. 33±4. 64) g/L and (2.93 ±0. 50)g/L respectively,which were obviously higher than that of the control group[ (2.13± 0.51 ) g/L, ( 11.25 ± 2.63 ) g/L and ( 1.21 ± 0.35 ) g/L ], The levels of C3 and C4 were (0.82 ± 0.19 ) g/L and (0.13±0.08) g/L,whieh were obviously lower than that of the control group[ (1.20±0.31 )g/L and(0.27 ±0.11 ) g/L] with statistically significance ( P 〈 0.05 ). The levels of Ig and complements of patients with different viral load had statistically difference ( P 〈 0. 05 ). Pearson correlation analysis showed HCV-RNA was positively correlated with Ig and negatively correlated with complements (P 〈 0. 05 ). Conclusion There are different levels of Ig and complements in patients with different HCV load. Therefore, viral load must be kept under control in order to reduce the injury of immune system.
出处 《国际免疫学杂志》 CAS 2017年第2期169-172,共4页 International Journal of Immunology
关键词 丙型肝炎 HCV—RNA 免疫球蛋白 补体 Hepatitis C HCV-RNA Immuno globulins Complements
  • 相关文献

参考文献3

二级参考文献34

  • 1Tatsuo Kanda,Shingo Nakamoto,Masato Nakamura,Xia Jiang,Tatsuo Miyamura,Shuang wu,Osamu Yokosuka.Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection[J].Journal of Clinical and Translational Hepatology,2014,2(1):1-6. 被引量:8
  • 2Cicek IE, Cicek E, Kayhan F, et al. The roles of BDNF, S100B, and oxidative stress in interferon-induced depression and the effect of an- tidepressant treatment in patients with chronic viral hepatitis: a prospective study[J]. J Psychosom Res, 2014, 76(3): 227-232.
  • 3Martin CS, Ionescu LN, Barbu CG, et al. Takotsubo cardiomyopathy and transient thyrotoxicosis during combination therapy with interferon- alpha and ribavirin for chronic hepatitis C [J]. BMC Endocr Disord, 2014, 14(1): 10.
  • 4Kokordelis P, Kramar B, K/Jmer C, et al, An effective interferon-gam- ma-mediated inhibition of hepatitis C virus replication by natural killer cells is associated with spontaneous clearance of acute hepatitis C in human immunodeficivncy virus-positive patients[J]. Hepatology, 2014, 59(3): 814-827.
  • 5Larrubia JR, Lokhande MU, Moreno-Cubero E, et al. HCV-specific CD8+ cell detection at week 12 of chronic hepatitis C treatment with PEG-interferon-c 2b/ribavirin correlates with infection resolution[J]. Cell Immunol, 2013, 286(1-2): 31-38.
  • 6Chcn AY, Zcremski M, Chauhan R, et al. Persistence of hepatitis C virus during and alter otherwise clinically successful treatment of chronic hepatitis C with standard pcgylated interferon ct-2b and rib- avirin therapy[J]. PLoS One, 2013, 8(11): 80078.
  • 7Younossi ZM, Singer ME, Mir HM, et al. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C geno-type 1 patients[J]. J Hepatol, 2014, 60(3): 530-537.
  • 8Stattermayer AF, Strassl R, Maieron A, et al. Polymorphisms of inter- feron-h 4 and IL28B - effects on treatment response to interferon/rib- avirin in patients with chronic hepatitis C [J]. Aliment Pharmacol Ther, 2014, 39(1): 104-111.
  • 9Hou XJ, Xu JH, Wang J, et al. Can antidepressants prevent pegylated interferon-edribavidn-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-con- trolled trials?[J]. PLoS One, 2013, 8(10): e76799.
  • 10Narita Y, Genda T, Tsuzura H, et al. Prediction of liver stiffiaess hep- atocellular carcinoma in chronic hepatitis C patients on interfer-on-based anti-viral therapy [J]. J Gastroenterol Hepatol, 2014, 29(1): 137-143.

共引文献11

同被引文献32

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部